Press release

Jarl Ulf Jungnelius resigns from Oncopeptides’ Board of Directors

February 05, 2025

Stockholm, February 5, 2025 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that Jarl Ulf Jungnelius has informed the Board of Directors of his decision to step down from the Bord of Directors of Oncopeptides in which he has served since 2011. This due to personal reasons related to a change of domicile from Sweden.

“With his extensive oncology experience Ulf has made important contributions to Oncopeptides, particularly during the development phase of Pepaxti,” says Per Wold-Olsen, Chairman of the Board at Oncopeptides. “We wish Ulf the best of luck in the future and thank him for his 14 years of service to the company”.